Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum

SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2018 BIO Investor Forum on Wednesday, October 17, 2018 at 3:00 p.m. Pacific Time. Ms. Johnson will present a Daré overview and provide an update on the Company’s portfolio programs.

The presentation will be webcast live and may be accessed by visiting Daré’s website at . A replay of the webcast will be available for 10 business days.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Topical 5% Sildenafil Citrate Cream, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit .

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (), SEC filings, press releases, public conference calls and webcasts.  Daré uses these channels to communicate with its investors and the public about the company and other issues. The information Daré posts on its investor relations website may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:

Ami Bavishi

Burns McClellan



212-213-0006

OR

Media on behalf of Daré Bioscience, Inc.:

Amanda Guisbond

Canale Communications



781-405-8775

Source: Daré Bioscience